Optimized Therapy in Severe Traumatic Brain Injured Patients

• Status: Completed
• Trial end date: 2011-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Severe traumatic brain injury is associated with life-threatening and incapacitating secondary injury.

Contemporary therapeutic interventions are aimed at preventing and treating secondary damage. In this context, improved cerebral metabolism is an important target in modern neurointensive care.

The main hypothesis is that continuous intravenous infusion of glutamyl-alanyl dipeptide restores disturbed brain metabolism following severe traumatic brain injury.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Zurich
• Collaborators: Fresenius Kabi; Swiss National Science Foundation; University Hospital, Zürich

Criteria

Inclusion Criteria:

• severe traumatic brain injury

• prolonged pharmacologic coma

• multimodal neuromonitoring (microdialysis, ptiO2)

• enteral nutrition

Exclusion Criteria:

• patients anticipated to decease within 48 hours

• abdominal injury

• mass transfusion

• renal impairment

• hepatic impairment

• barbiturate coma

• parenteral nutrition

• weight below 50 kg

• weight above 100 kg